Katelyn Krivchenia1,2, Dmitry Tumin3,4,5, Joseph D Tobias6,4,5, Don Hayes3,7,8,4,9. 1. Center for the Epidemiological Study of Organ Failure and Transplantation, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205, USA. katelyn.krivchenia@nationwidechildrens.org. 2. Section of Pulmonary Medicine, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205, USA. katelyn.krivchenia@nationwidechildrens.org. 3. Department of Pediatrics, The Ohio State University College of Medicine, 370 W. 9th Ave, Columbus, OH, 43210, USA. 4. Center for the Epidemiological Study of Organ Failure and Transplantation, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205, USA. 5. Department of Anesthesiology & Pain Medicine, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205, USA. 6. Department of Anesthesiology & Pain Medicine, The Ohio State University College of Medicine, 370 W. 9th Ave, Columbus, OH, 43210, USA. 7. Department of Internal Medicine, The Ohio State University College of Medicine, 370 W. 9th Ave, Columbus, OH, 43210, USA. 8. Department of Surgery, The Ohio State University College of Medicine, 370 W. 9th Ave, Columbus, OH, 43210, USA. 9. Section of Pulmonary Medicine, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205, USA.
Abstract
PURPOSE: Cystic fibrosis (CF) is a progressive disease resulting in end-stage lung disease. Lung transplantation (LTx) is an important consideration in these patients. Studies have suggested greater post-LTx mortality among CF patients with public insurance. We evaluated the influence of insurance status on survival among CF patients during their time on the LTx waitlist. METHODS: Adult LTx candidates diagnosed with CF and listed since the implementation of the lung allocation score, from May 2005 until September 2013, were identified in the United Network for Organ Sharing database. Waitlist mortality was compared across projected primary payment type (private insurance or self-pay; Medicaid; Medicare) using Kaplan-Meier functions and Fine-Gray competing-risks survival analysis, accounting for the competing risk of transplantation. RESULTS: 1770 LTx candidates with CF were included in univariate survival analyses, with Medicaid increasing waitlist mortality hazard relative to private insurance (HR 2.28; 95 % CI 1.62, 3.21; p < 0.001) and relative to Medicare (HR 2.23; 95 % CI 1.43, 3.48; p < 0.001). A multivariable competing-risks model confirmed greater waitlist mortality among Medicaid patients relative to private insurance (HR 2.57; 95 % CI 1.56, 4.23; p < 0.001) or patients with Medicare (HR 4.02; 95 % CI 1.98, 8.17; p < 0.001) after adjusting for potential confounders. No differences in waitlist survival were found between Medicare and private insurance. CONCLUSIONS: CF patients with Medicaid insurance have higher risk of death while awaiting LTx when compared to patients with Medicare or private insurance. The impact of insurance status on survival in this population begins before LTx and compounds the disparities previously observed in post-transplant outcomes.
PURPOSE:Cystic fibrosis (CF) is a progressive disease resulting in end-stage lung disease. Lung transplantation (LTx) is an important consideration in these patients. Studies have suggested greater post-LTx mortality among CFpatients with public insurance. We evaluated the influence of insurance status on survival among CFpatients during their time on the LTx waitlist. METHODS: Adult LTx candidates diagnosed with CF and listed since the implementation of the lung allocation score, from May 2005 until September 2013, were identified in the United Network for Organ Sharing database. Waitlist mortality was compared across projected primary payment type (private insurance or self-pay; Medicaid; Medicare) using Kaplan-Meier functions and Fine-Gray competing-risks survival analysis, accounting for the competing risk of transplantation. RESULTS: 1770 LTx candidates with CF were included in univariate survival analyses, with Medicaid increasing waitlist mortality hazard relative to private insurance (HR 2.28; 95 % CI 1.62, 3.21; p < 0.001) and relative to Medicare (HR 2.23; 95 % CI 1.43, 3.48; p < 0.001). A multivariable competing-risks model confirmed greater waitlist mortality among Medicaid patients relative to private insurance (HR 2.57; 95 % CI 1.56, 4.23; p < 0.001) or patients with Medicare (HR 4.02; 95 % CI 1.98, 8.17; p < 0.001) after adjusting for potential confounders. No differences in waitlist survival were found between Medicare and private insurance. CONCLUSIONS:CFpatients with Medicaid insurance have higher risk of death while awaiting LTx when compared to patients with Medicare or private insurance. The impact of insurance status on survival in this population begins before LTx and compounds the disparities previously observed in post-transplant outcomes.
Authors: Mary Amanda Dew; Andrea F Dimartini; Annette De Vito Dabbs; Rachelle Zomak; Sabina De Geest; Fabienne Dobbels; Larissa Myaskovsky; Galen E Switzer; Mark Unruh; Jennifer L Steel; Robert L Kormos; Kenneth R McCurry Journal: Transplantation Date: 2008-01-27 Impact factor: 4.939
Authors: David Weill; Christian Benden; Paul A Corris; John H Dark; R Duane Davis; Shaf Keshavjee; David J Lederer; Michael J Mulligan; G Alexander Patterson; Lianne G Singer; Greg I Snell; Geert M Verleden; Martin R Zamora; Allan R Glanville Journal: J Heart Lung Transplant Date: 2014-06-26 Impact factor: 10.247
Authors: Jeremiah G Allen; George J Arnaoutakis; Jonathan B Orens; John McDyer; John V Conte; Ashish S Shah; Christian A Merlo Journal: J Heart Lung Transplant Date: 2011-01 Impact factor: 10.247
Authors: Don Hayes; Dmitry Tumin; Curt J Daniels; Karen S McCoy; Heidi M Mansour; Joseph D Tobias; Stephen E Kirkby Journal: Ann Thorac Surg Date: 2015-12-11 Impact factor: 4.330
Authors: C A Merlo; S C Clark; G J Arnaoutakis; N Yonan; D Thomas; A Simon; R Thompson; H Thomas; J Orens; A S Shah Journal: Am J Transplant Date: 2015-03-24 Impact factor: 8.086
Authors: Richard A Belkin; Noreen R Henig; Lianne G Singer; Cecilia Chaparro; Ronald C Rubenstein; Sharon X Xie; Justin Y Yee; Robert M Kotloff; David A Lipson; Greta R Bunin Journal: Am J Respir Crit Care Med Date: 2005-12-30 Impact factor: 21.405
Authors: David J Lederer; Emma K T Benn; R Graham Barr; Jessie S Wilt; Genevieve Reilly; Joshua R Sonett; Selim M Arcasoy; Steven M Kawut Journal: Am J Respir Crit Care Med Date: 2007-11-15 Impact factor: 21.405
Authors: Bradley S Quon; Kevin Psoter; Nicole Mayer-Hamblett; Moira L Aitken; Christopher I Li; Christopher H Goss Journal: Am J Respir Crit Care Med Date: 2012-09-13 Impact factor: 21.405
Authors: Alexander S Goldfarb-Rumyantzev; James K Koford; Bradley C Baird; Madhukar Chelamcharla; Arsalan N Habib; Ben-Jr Wang; Shih-jui Lin; Fuad Shihab; Ross B Isaacs Journal: Clin J Am Soc Nephrol Date: 2006-01-11 Impact factor: 8.237